Thus, tumors from the HR+/HER2+ category had a relatively favorable prognosis similar to HR+/HER2- cancers (hazard ratio 1.26 compared to HR+/HER2-, P = 0.770; 3-year survival rate 90.0%). Here, ERBB2 is linked to cancer.